Law & Regulation
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech…
FSD Pharma Inc. (NASDAQ: HUGE / CSE: HUGE / FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the completion of dosing the first cohort of patients in the Company’s Phase I clinical trial of Lucid-21-302 (“Lucid-MS”). The clinical trial (ClinicalTrials.gov Identifier: NCT05821387 ), being conducted by FSD Pharma through the Company’s wholly owned subsidiary Lucid Psycheceuticals, is a first-in-human study evaluating Lucid-MS, a small molecule inhibitor of hypercitrullination, as a novel drug candidate for the treatment of Multiple Sclerosis (“MS”).
Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals“Our clinical development team and international advisory committee are delighted at the progress of this milestone and completing dosing the first cohort. The safety review committee has recommended to move forward with the next cohort dosing, which we are thrilled to say is expected to commence in the next few days.”
The clinical trial is a randomized, double-blind, placebo controlled, single ascending dose (“SAD”) and multiple ascending dose (“MAD”) study with the primary outcomes evaluating the safety, tolerability, and pharmacokinetics of Lucid-MS in healthy volunteers under fed and fasted conditions. Enrollment will be comprised of five SAD cohorts and two MAD cohorts. Each SAD and MAD cohort will enroll eight participants (for a total of 56 participants) randomized to six active and two placebo groups. Participants in the active group will receive single or multiple doses of Lucid-MS. For the SAD cohort with food effect, all eight participants will receive Lucid-MS.
Lucid-MS is a patented first-in-class, New Chemical Entity (“NCE”) and a neuroprotective compound with a novel mechanism of action for the treatment of MS. In preclinical models, Lucid-MS has been shown to prevent myelin degradation (demyelination), a hallmark pathology feature of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. Preclinical evidence has demonstrated Lucid-MS to promote functional recovery in experimental animal models of MS ( https://fsdpharma.com/our-science/ ). Based on current evidence, Lucid-MS is non-immunomodulatory agent, an important distinction in the potential for developing new, safe options for treating MS.
About FSD Pharma
FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the Company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic